Showing 761-770 of 805 results for "".
- Shamir Group Employees Around the World are Mobilized for Humanitarian Aid for Ukrainian Refugees in Warsawhttps://modernod.com/news/shamir-group-employees-around-the-world-are-mobilized-for-humanitarian-aid-for-ukrainian-refugees-in-warsaw/2480745/Shamir is now voluntarily operating traveling laboratories for testing and fitting of eyeglasses among Ukrainian refugees, located at the Patk Expo complex in Warsaw, Poland. The mobile laboratories on wheels are equipped with advanced technology for rapid production of advanced lenses&mdash
- Hanita Lenses Launches Joint Venture with Ophthalmic Vision Care in the Iberian Peninsulahttps://modernod.com/news/hanita-lenses-launches-joint-venture-with-ophthalmic-vision-care-in-the-iberian-peninsula/2480732/Hanita Lenses announced a new joint venture with Madrid, Spain-based Ophthalmic Vision Care (OVC), a distributor IOLs for Hanita Lenses in Spain since 2016. The joint venture, named "Hanita Iberica," merges the assets of OVC—as a service provider of d
- Haag-Streit Introduces the Imaging Module 910 Slit Lamphttps://modernod.com/news/haag-streit-launhces-the-imaging-module-910-slit-lamp/2480718/Haag-Streit announced the launch of the Imaging Module 910 slit lamp. The device is instantly ready by the turn of a knob and does not require using software. Haag-Streit says capturing images is equally easy—pressing the camera trigger button is all that it takes. "
- Harrow Health Acquires US Commercial Rights to Four Branded Eye Drops from Novartishttps://modernod.com/news/harrow-health-imprimisrx-acquires-us-commercial-rights-to-four-branded-eye-drops-from-novartis/2480527/Harrow Health, the parent company of ImprimisRx, announced its has acquired the exclusive US commercialization rights of four FDA-approved ophthalmic medicines—Iopidine 1% and 0.5% (apraclonidine hydroc
- Haag-Streit to Focus on Surgical Microscopes in Ophthalmologyhttps://modernod.com/news/haag-streit-to-focus-on-surgical-microscopes-in-ophthalmology/2480524/Haag-Streit announced that it was focus its business moving forward on ophthalmology—discontinuting its surgical product portfolio in neurosurgery, spine surgery, ENT and plastic-reconstructive surgery. "For our customers, this focus on eye care will allow us to offer so
- CooperVision Specialty EyeCare Launches Optimized Pupil Optics for Onefit MED and Onefit MED+ Scleral Lenseshttps://modernod.com/news/coopervision-specialty-eyecare-launches-optimized-pupil-optics-for-onefit-med-and-onefit-med-scleral-lenses/2480394/CooperVision Specialty EyeCare announced the launch of Optimized Pupil Optics (OPO) for its Onefit MED and Onefit MED+ scleral contact lenses to eye care providers (ECPs) in the United States and Canada. The new high precision design option—which is supported by an
- Luminopia One Demonstrates Safety and Efficacy in Phase 3 Pivotal Trial for Amblyopiahttps://modernod.com/news/luminopia-one-demonstrates-safety-and-efficacy-in-phase-3-pivotal-trial/2480274/Luminopia announced the publication of positive phase 3 pivotal data of its investigational treatment for amblyopia—Luminopia One. Published in Ophthalmology, the study was conducted at 21 academic and community sites in the U.S., in which childre
- Alcon Launches Systane Hydration Multi-Dose Preservative-Free Lubricant Eye Drops in the U.S.https://modernod.com/news/alcon-launches-systane-hydration-multi-dose-preservative-free-lubricant-eye-drops-in-the-u-s/2479131/Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. launch of the newest addition to its innovative portfolio of dry eye products – Systane® Hydration Multi-Dose Preservative-Free (MDPF) Lubricant Eye Dro
- Gemini Therapeutics Enrolls First Patient in Phase 1 Study of GEM103 for Dry AMDhttps://modernod.com/news/gemini-therapeutics-enrolls-first-patient-in-phase-1-study-of-gem103-for-dry-amd/2477214/Gemini Therapeutics announced it has initiated enrollment in its phase 1 study of GEM103, a recombinant, native Complement Factor H (CFH) for the treatment of dry age-related macular degeneration. AMD is the leading cause of irreversible blindness in the western world—affecting millions of
- Valeda Light Delivery System Receives 2019 Medical Design Excellence Awardhttps://modernod.com/news/valeda-light-delivery-system-receives-2019-medical-design-excellence-award/2476654/LumiThera and Product Creation Studio announced that LumiThera’s Valeda Light Delivery System has won a silver award in the 21st Annual Medical Design Excellence Awards competition. The 2019 winners were announced at the MDEA Ceremony on Tuesday, June 11, 2